Find Academic Supervisors

Veronique BonnetView profile

Professor

• Glycochemistry
• Nanotechnology
• Drug Delivery Systems
• +4 more

Professor Veronique Bonnet is a leading researcher at the Glycochemistry and Agroresources Laboratory of Amiens (UR 7378) at Université de Picardie Jules Verne. Her work bridges carbohydrate chemistry, nanotechnology, and pharmaceutical sciences, focusing on developing innovative cyclodextrin-based systems for drug delivery and materials science applications. Professor Bonnet's research primarily centers on sugar-protein recognition and vectorization , with special emphasis on overcoming biological barriers like the blood-brain barrier. Her laboratory develops amphiphilic cyclodextrin derivatives that self-assemble into nanocarriers capable of transporting therapeutic agents across these barriers. She has made significant contributions to understanding cyclodextrin-metal interactions, carbohydrate conformation analysis using ion mobility mass spectrometry, and developing selective enzyme inhibitors for diabetes treatment. Her recent publications (2021-2023) demonstrate a diverse research portfolio spanning pharmaceutical applications, analytical methodology development, and sustainable materials science. Notably, her work on enzymatically modified pectins from fruit waste has shown exceptional promise as polymer binders for next-generation lithium-ion batteries, demonstrating the interdisciplinary nature of her research. Professor Bonnet has been authorized to supervise research since 2013 and maintains an active research program with numerous publications in high-impact journals across chemistry, materials science, and pharmaceutical fields. Her laboratory serves as a hub for interdisciplinary research connecting carbohydrate chemistry with practical applications in medicine and technology.

José KovenskyView profile

Professor

• Glycochemistry
• Oligosaccharides
• Glycosaminoglycans
• +3 more

José Kovensky is a Professor and Director of the Laboratory of Glycochemistry and Agro-Resources (LG2A UR 7378) at the University of Picardie Jules Verne. His research integrates synthetic chemistry, biomaterials science, and environmental technology, with a focus on carbohydrate-derived compounds for biomedical and industrial applications. His primary research interests include: Glycochemistry : Synthesis of sulfated oligosaccharides, glycosaminoglycan mimetics, and multivalent ligands to modulate biological processes like inflammation and wound healing. Environmental Remediation : Development of glycoside-based surfactants for metal flotation to decontaminate soil and water. Waste Valorization : Extraction of bioactive oligosaccharides from agrofood wastes (e.g., orange peel, apple pomace) for use as plant elicitors or prebiotics. Drug Delivery : Functionalization of nanocarriers (e.g., liposomes) with defined oligosaccharides for targeted cancer therapy. Recent publications (2019–2024) reveal a strong emphasis on translating fundamental carbohydrate chemistry into applied solutions: Wound healing accelerators from marine algae sulfated galactans. Heparanase/TLR4 inhibitors for inflammatory diseases. Sustainable production of oligosaccharides from biomass. Osteoblast-mineralizing carbohydrate derivatives for bone repair. His laboratory leverages advanced techniques including NMR, MALDI-TOF-MS, and enzymatic assays to characterize novel glycoconjugates and validate their biological activity. Collaborative projects span multiple countries, underscoring the global impact of his work in glycobiology and green chemistry.

• Biochemistry
• Chemical Biology
• Redox Signaling
• +7 more

Brian C. Smith, PhD, is an Associate Professor in the Department of Biochemistry at the Medical College of Wisconsin (MCW), with adjunct roles at Marquette University. His affiliations include leadership as Associate Director of the Program in Chemical Biology and memberships in MCW's Cancer Center, Cardiovascular Research Center, and Center for Disease Prevention Research. He holds a PhD from the University of Wisconsin-Madison and completed postdoctoral training at UC Berkeley and Scripps Research. Dr. Smith's research spans redox biochemistry , epigenetic regulation , and enzyme mechanisms , focusing on post-translational modifications like S-nitrosation and lysine acylation. His lab studies sirtuin deacetylases, BET bromodomains, and nitric oxide signaling using techniques such as mass spectrometry, NMR, and chemical probe development. Major themes include: Developing bromodomain inhibitors for diabetes and cancer Deciphering redox control of protein function Engineering selective epigenetic modulators His recent publications (2023–2025) emphasize BET bromodomain therapeutics , sirtuin oxidative regulation , and redox metabolism in disease , with frequent appearances in high-impact journals like J Biol Chem , Cell Chem Biol , and ACS Chemical Biology . Honors include: MCW Outstanding Graduate Educator Award (2018) MCW Faculty Service Award (2019) Phi Beta Kappa & Bronze Tablet (Top 3% graduate, UIUC) NIH F31/R35 grants with impact scores of 12–17 (top percentiles) He actively mentors PhD students and postdocs, with funded projects totaling over $3M from NIH, ADA, and AHA. His lab collaborates with cardiovascular and cancer research teams, leveraging MCW's core facilities in structural genomics and redox biology.

Matthew I. GibsonView profile

Professor

• Glycosciences
• Biomaterials
• Polymer Chemistry
• +3 more

Professor Matthew I. Gibson holds a joint appointment between the University of Warwick's Department of Chemistry and Warwick Medical School . A Royal Society Industry Research Fellow and ERC Consolidator Grant recipient, he leads the iCASE Scheme at the MRC-funded Doctoral Training Center and co-founded CryoLogyx Ltd. Education MChem, 1st Class (2003), University of Durham PhD in Macromolecular Chemistry (2007), University of Durham Postdoc, EPFL (2007-2009) Research focuses on glycosciences and biomaterials for cryopreservation, infection detection, and cell surface modification. His group develops glycosylated nanomaterials and ice recrystallization inhibitors with applications in cell therapy storage and diagnostics. Current projects include the EU-funded Nanocarb and ICE_PACK (ERC) initiatives. Selected Publications address glycomaterial selectivity (2021, JACS Au), polymer-enhanced ice control (2021, JACS), cyclic ice-binding peptides (2021, Nature), and glycosylated nanoparticle diagnostics (2022, Chemical Society Reviews). Key keywords: Glycobiology, Biomimetic Materials, Polymer Nanotechnology, Antifreeze Proteins Scientific Awards include the McBain Medal , RSC Emerging Technology Prize , and multiple Young Investigator recognitions from Biomacromolecules and MacroGroupUK. Teaching includes modules on polymers, glycosciences, and living polymerization. He (co-)supervises 15+ PhD students in glyconanomaterials, cryoprotectants, and cell engineering projects.

• Medicinal Chemistry
• Chemical Biology
• Organic Synthesis
• +3 more

Professor Jörg Rademann holds a faculty position at Free University of Berlin's Institute of Pharmacy within the Department of Biology, Chemistry, Pharmacy. His research bridges synthetic organic chemistry with biochemical and immunological applications to develop therapeutic compounds and molecular tools. Research foci include: Medicinal Chemistry : Design of protease inhibitors, Toll-like receptor modulators, and phosphopeptide biomimetics Chemical Biology : Multivalent ligands for intracellular protein receptors and PDZ domain interaction studies Synthetic Innovation : Diversity-oriented rhamnolipid synthesis and chemoenzymatic production of sulfated oligohyaluronans His program is sustained by active DFG funding, notably a Collaborative Research Center project on hyperfluorinated biomimetics. Past work encompasses immunostimulant characterization, signal transduction modulation via peptide polymers, and protein-ligand crystallization. Professor Rademann maintains advanced instrumentation including an HPLC-QTOF-MS system acquired through dedicated equipment funding. His research operates within the Institute of Pharmacy framework and leverages national collaborative networks via Transregio and SFB programs for multi-institutional scientific integration.

• Enzymology
• Drug Discovery
• Biomolecular Interaction Analysis
• +7 more

Professor Helena Danielson is a distinguished academic at Uppsala University, serving as Professor of Biochemistry since 2002. She leads the Danielson group within the Department of Chemistry - BMC (Biomedical Centre) and holds the position of Platform Scientific Director at the SciLifeLab infrastructure unit for Biophysical Screening and Characterization. Dr. Danielson is also a co-founder of Beactica Therapeutics AB, demonstrating her strong connection between academic research and commercial drug discovery applications. Her research expertise centers on enzymology and drug discovery, with particular focus on biomolecular interaction analysis for detailed studies of enzyme-inhibitor interactions and other critical recognition processes in life sciences. Her work has extensively investigated various enzymes, primarily proteases and polymerases from viruses and other infectious organisms, or those involved in important disease processes. Dr. Danielson has over 30 years of experience in the commercial drug discovery process through collaborative research with pharmaceutical and biotechnological industry partners. Analysis of her recent publications reveals a strong emphasis on RNA-protein interactions, epigenetic targets (particularly SMYD3), and advanced biosensor technologies for drug discovery. Her work increasingly integrates computational methods with experimental biosensor approaches, especially using Surface Plasmon Resonance (SPR) technology for fragment-based screening against challenging drug targets. The research shows progression from traditional enzyme kinetics to more sophisticated analyses of multivalent interactions, allosteric regulation, and water network effects in protein-ligand binding. As Platform Scientific Director at SciLifeLab, Dr. Danielson oversees critical infrastructure for biophysical screening and characterization. Her group has developed numerous innovative methodologies for studying protein-ligand interactions, including multiplexed experimental strategies and sensitive detection methods. Her leadership extends to fostering collaborations between academic researchers and industry partners, facilitating the translation of basic research into practical drug discovery applications.